International

Elon Musk produces brain chip that enables disabled patients to move, see and communicate

After the firm missed prior deadlines he had set, Elon Musk said on Wednesday that he anticipates a wireless brain chip developed by his company Neuralink to start human clinical testing in six months.

The business is working on brain chip interfaces that, according to its claims, might let crippled people move and communicate once again. Musk added on Wednesday that the program will also focus on recovering vision.

Neuralink, a company with offices in the San Francisco Bay Area and Austin, Texas, has recently been testing its products on animals while waiting for the U.S. Food and Drug Administration (FDA) to give the go-ahead for human clinical trials.

After the firm missed prior deadlines he had set, Elon Musk said on Wednesday that he anticipates a wireless brain chip developed by his company Neuralink to start human clinical testing in six months.

The business is working on brain chip interfaces that, according to its claims, might let crippled people move and communicate once again. Musk added on Wednesday that the program will also focus on recovering vision.

Neuralink, a company with offices in the San Francisco Bay Area and Austin, Texas, has recently been testing its products on animals while waiting for the U.S. Food and Drug Administration (FDA) to give the go-ahead for human clinical trials.

Musk stated at a long-awaited public update on the device, “We want to be really meticulous and ensure that it will work properly before putting a device into a human.”

Musk underlined the speed at which the business is creating its device during a nearly three-hour presentation to a restricted group of invitees at Neuralink’s headquarters.

To get permission from the American Food and Drug Administration (FDA) to start clinical trials in people, Neuralink carried out research on animals.
To get permission from the American Food and Drug Administration (FDA) to start clinical trials in people, Neuralink carried out research on animals.
“The progress at first will appear possibly agonizingly slow, especially as it relates to humans, but we are doing all of the things to bring it to scale in parallel,” he continued.

Therefore, advancement ought to be exponential in theory.

The first two human applications targeted by the Neuralink device will be in restoring vision and enabling movement of muscles in people who cannot do so, Musk said. “Even if someone has never had vision, ever, like they were born blind, we believe we can still restore vision,” he said. Musk said that he wants to be certain that it will work before putting the device into a human. Musk said that he wants to be certain that it will work before putting the device into a human.

The event was originally planned for Oct. 31 but Musk postponed it just days before without giving a reason. Neuralink’s last public presentation, more than a year ago, involved a monkey with a brain chip that played a computer game by thinking alone. Musk, who also runs electric vehicle manufacturer Tesla, rocket firm SpaceX, and social media platform Twitter, is known for lofty goals such as colonizing Mars and saving humanity.

His ambitions for Neuralink, which he launched in 2016, are of the same grand scale. Elon Musk’s Neuralink allegedly subjected monkeys to ‘extreme suffering’ He wants to develop a chip that would allow the brain to control complex electronic devices and eventually allow people with paralysis to regain motor function and treat brain diseases such as Parkinson’s, dementia and Alzheimer’s. He also talks of melding the brain with artificial intelligence.

Neuralink, however, is running behind schedule. Musk said in a 2019 presentation he was aiming to receive regulatory approval by the end of 2020. He then said at a conference in late 2021 that he hoped to start human trials this year.

Current and former workers claim that Neuralink has routinely missed internal deadlines for obtaining FDA approval to begin human studies. According to Reuters, Musk approached rival Synchron early this year about a prospective investment after complaining to Neuralink staff members about their sluggish development.

By successfully implanting its device in a patient in the United States for the first time in July, Synchron achieved a significant milestone. In 2021, it received regulatory approval from the US for use in human trials, and studies involving four Australians have been completed.

Related Articles

Leave a Reply

Check Also
Close
Back to top button
%d bloggers like this:

Adblock Detected

Please consider supporting us by disabling your ad blocker